Ocugen Inc
Change company Symbol lookup
Select an option...
OCGN Ocugen Inc
SMBK SmartFinancial Inc
STAF Staffing 360 Solutions Inc
TEL TE Connectivity Ltd
BOKF BOK Financial Corp
PRAA PRA Group Inc
FHN First Horizon Corp (Tennessee)
XEL Xcel Energy Inc
XEC Cimarex Energy Co
XCUR Exicure Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).

Price
Delayed
$7.31
Day's Change
0.81 (12.46%)
Bid
--
Ask
--
B/A Size
--
Day's High
7.70
Day's Low
6.58
Volume
(Heavy Day)

Today's volume of 32,120,410 shares is on pace to be much greater than OCGN's 10-day average volume of 29,513,585 shares.

32,120,410
Latest Earnings Met Consensus (Q4 ending 12/2020)Next Earnings Announcement
Q4
Announced March 18, 2021
-$0.03Q4 Estimate range
of 4 analysts
-$0.02 to -$0.02Q1 Earnings
will announce
(Unconfirmed) May 6, 2021

Quarterly Earnings History and Estimates

Show high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

Display:

UpdateCancel

OCGN's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.